



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)

Anrukinzumab

Cat. No.:	HY-P99439
CAS No.:	910649-32-0
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma ^{[1][2][3]} .									
IC₅₀ & Target	IL-13 ^{[1][2][3]} .									
In Vivo	<p>Anrukinzumab (IMA-638; 10 mg/kg; intravenous infusion; single) reduces lung inflammation in cynomolgus monkey model of lung inflammation^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Adult male cynomolgus monkeys (6 to 10 kg; cynomolgus monkey model of lung inflammation)^[1].</td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous infusion; single</td> </tr> <tr> <td>Result:</td> <td>Reduced total BAL cell count, eosinophil number, and neutrophil number. Reduced the levels of eotaxin and RANTES in BAL fluid.</td> </tr> </table>		Animal Model:	Adult male cynomolgus monkeys (6 to 10 kg; cynomolgus monkey model of lung inflammation) ^[1] .	Dosage:	10 mg/kg	Administration:	Intravenous infusion; single	Result:	Reduced total BAL cell count, eosinophil number, and neutrophil number. Reduced the levels of eotaxin and RANTES in BAL fluid.
Animal Model:	Adult male cynomolgus monkeys (6 to 10 kg; cynomolgus monkey model of lung inflammation) ^[1] .									
Dosage:	10 mg/kg									
Administration:	Intravenous infusion; single									
Result:	Reduced total BAL cell count, eosinophil number, and neutrophil number. Reduced the levels of eotaxin and RANTES in BAL fluid.									

REFERENCES

- [1]. Bree A, et al. IL-13 blockade reduces lung inflammation after *Ascaris suum* challenge in cynomolgus monkeys. *J Allergy Clin Immunol.* 2007 May;119(5):1251-7.
- [2]. Reinisch W, et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. *Gut.* 2015 Jun;64(6):894-900.
- [3]. Elias JA, et al. IL-13 in asthma. The successful integration of lessons from mice and humans. *Am J Respir Crit Care Med.* 2011 Apr 15;183(8):957-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA